Status:
UNKNOWN
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
Lead Sponsor:
Ciusss de L'Est de l'Île de Montréal
Collaborating Sponsors:
Covid-19 Early Treatment Fund
Conditions:
Viral Pneumonia
Serotonin Syndrome
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
This randomized controled open label clinical trial is to evaluate the effect of Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.
Detailed Description
Observational and biochemical studies have identified an interesting pathway in the pathophysiology of certain clinical-biological characteristics of COVID-19, linked to an excess of serotonin. We hyp...
Eligibility Criteria
Inclusion
- Men and women age 18 or older
- Hospitalized and requiring medical care for COVID-19
- Presenting respiratory failure cause by COVID 19 requiring oxygen and/or mechanical ventilation support
- With radiographic evidence of pulmonary infiltrate
- Able to give informed consent or, if unable to do so regarding the medical condition, having relatives able of consenting for the patient
Exclusion
- Pregnancy
- Patients with pre-existing terminal condition with life expectancy \< 6 months
- Patients with pre-existing severe lung disease requiring home O2
- History of seizure disorder
- History of adverse reaction to antihistamines or to Cyproheptadine
Key Trial Info
Start Date :
April 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04820751
Start Date
April 10 2021
End Date
January 1 2022
Last Update
April 2 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.